Health Trials

Solid Tumor Refractory to Conventional Treatment

2

Review clinical trials related to Solid Tumor Refractory to Conventional Treatment. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Participants needed: 25
Trial details
Phase: Phase 1, Phase 2Age: 3+Biological sex: AllType: InterventionalSponsor: Fundación de investigación HMUpdated: Jun 4, 2026Locations: 1
Eligibility criteria

18 months - 18 years of age at the time of the initial diagnosis. [+22]

Previous significant drug-induced hepatitis toxicity experienced in the past tha... [+7]

Read more
Status: Not yet recruiting

Phase I Study of FXS887 in the Treatment of Solid Tumors

This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.

Participants needed: 14
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Updated: Jan 16, 2026Locations: 1
Eligibility criteria

Aged ≥ 18 years, male or female; [+7]

Within the washout period of prior anti-tumor medication treatment (4 weeks or 5... [+21]

Read more